Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
JCO Glob Oncol ; 9: e2200221, 2023 03.
Artigo em Inglês | MEDLINE | ID: mdl-36921242

RESUMO

PURPOSE: To examine cancer patients' perspectives on the impact of COVID-19 on teleoncology in Nigeria. METHODS: Data from a multicenter survey conducted at 15 outpatient clinics to 1,097 patients with cancer from April and July 2020 were analyzed. The study outcome was telemedicine, defined as patients who reported their routine follow-up visits were converted to virtual visits because of COVID-19 (coded yes/no). Covariates included patient age, ethnicity, marital status, income, cancer treatment, service disruption, and cancer diagnosis/type. Stata/SE.v.17 (StataCorp, College Station, TX) was used to perform chi-square and logistic regression analyses. P values ≤ .05 were considered statistically significant. RESULTS: The majority of the 1,097 patients with cancer were female (65.7%) and age 55 years and older (35.0%). Because of COVID-19, 12.6% of patients' routine follow-ups were converted to virtual visits. More patients who canceled/postponed surgery (17.7% v 7.5%; P ≤ .001), radiotherapy (16.9% v 5.3%; P ≤ .001), and chemotherapy (22.8% v 8.5%; P ≤ .001), injection chemotherapy (20.6% v 8.7%; P ≤ .001) and those who reported being seen less by their doctor/nurse (60.3% v 11.4%; P ≤ .001) reported more follow-up conversions to virtual visits. In multivariate analyses, patients seen less by their doctors/nurses were 14.3 times more likely to have their routine follow-ups converted to virtual visits than those who did not (odds ratio, 14.33; 95% CI, 8.36 to 24.58). CONCLUSION: COVID-19 caused many patients with cancer in Nigeria to convert visits to a virtual format. These conversions were more common in patients whose surgery, radiotherapy, chemotherapy, and injection chemotherapy treatments were canceled or postponed. Our findings suggest how COVID-19 affects cancer treatment services and the importance of collecting teleoncological care data in Nigeria.


Assuntos
COVID-19 , Neoplasias , Humanos , Feminino , Masculino , Pessoa de Meia-Idade , Pacientes Ambulatoriais , Neoplasias/terapia , Instituições de Assistência Ambulatorial , Etnicidade
3.
JCO Glob Oncol ; 8: e2100244, 2022 02.
Artigo em Inglês | MEDLINE | ID: mdl-35157511

RESUMO

PURPOSE: Because of the global COVID-19 pandemic, health care organizations introduced guidelines for modifications to health and cancer medical care delivery to mitigate transmission and ensure quality health outcomes. To examine the extent and impact of these modifications on oncology service disruptions in Nigeria, we surveyed oncology patients across selected public and private cancer treatment centers. MATERIALS AND METHODS: Participating in the study were 15 tertiary cancer treatment centers across 12 Nigerian states. We recruited adult patients with cancer (18+ years) on active treatment to complete a self-administered survey on cancer care during COVID-19. We conducted descriptive and multivariate data analysis using Stata 16.1. RESULTS: Respondents were (n = 1,072), female (65.7%), ages 18-49 years (50.3%), and married (80.7%). The top two cancers were breast and prostate. Overall, 17.3% of respondents reported disruptions to cancer care, and more than half (51.0%) reported difficulties accessing care. Changes in chemotherapy regimens or route of administration were reported in 8.4% of respondents. Odds for any disruption were highest for older patients, western states, patients with prostate cancer, and patients with two or more flu symptoms. Odds for radiotherapy cancellation were highest for older patients, those with prostate cancer, and those with medium service perception. CONCLUSION: This study investigated COVID-19-influenced cancer treatment disruptions in Nigeria. Patients with cancer experienced significant disruptions to cancer care. Vulnerable patients are most likely to be negatively affected. Policies and strategies aimed at minimizing service disruptions while maintaining cancer patients' safety should be a priority for all health care institutions in the COVID-19 era.


Assuntos
COVID-19 , Neoplasias , Adolescente , Adulto , Feminino , Humanos , Masculino , Oncologia , Pessoa de Meia-Idade , Neoplasias/epidemiologia , Neoplasias/terapia , Nigéria/epidemiologia , Pandemias , SARS-CoV-2 , Adulto Jovem
4.
Ecancermedicalscience ; 15: 1253, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34267809

RESUMO

The rapidly rising cancer burden and mortality rate in Africa are in contrast to the increase in cancer survivorship in Europe and North America. Genomic medicine has contributed to the rise in survival and has facilitated precision cancer control. However, there is a shortage of African representation in genomic databases, even for cancers that disproportionately affect Africans. To improve this outlook and address research in genomics and genetics relevant to Africa and people of African descent, the African Organisation for Research and Training in Cancer (AORTIC), under the Research Committee's auspices, organised the Cancer Genomic Conference. The conference aimed to develop a roadmap for cancer genomics research to control the continent's increasing cancer burden. Presentations at the conference revealed that: (1) Africa is made up of a highly heterogeneous group of people with diverse ethnic groups, (2) Very few African countries have been the focus of cancer genomics research, (3) Cancer exacts a heavy burden on global populations across the African diaspora with obvious genetic variants and cancer disparities and (4) There are differences in the contribution of genetics by race or ancestry and these differences are likely due to evolutionary genetics, contextual factors and genomic architecture. The importance of data security, ethics and integrity of the African genomics data was emphasised. The implementation of the conference highlights will provide the bedrock for pharmacogenomics to guide treatment decisions for cancer in Africa. The conference concluded with the formation of an AORTIC Special Interest Group on cancer genomics. It is the goal of this group to drive the implementation of this Conference's outcomes.

6.
Front Oncol ; 10: 573036, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-33330046

RESUMO

BACKGROUND: Globally, cancer is a major leading health problem with an estimated 10 million incidences and 6 million cancer deaths annually. In Nigeria, an estimated 72,000 cancer deaths occur annually, and 102,000 new cases are diagnosed from its population of 200 million people. These are, however, estimates, it is necessary to document the yearly trends and patterns of cancer mortality with regards to the different regions in the country. METHODOLOGY: we conducted this study at the Lagos State University Teaching hospital (LASUTH), Ikeja, Lagos to document mortality patterns from 2009 to 2018. Data extracted included those from the patient's case notes, admission and death registers, and death certificates. we also had records from the hospital records department and medical wards. We then documented cancer mortality over the study period. RESULTS: A total number of 6,592 deaths were recorded over ten years, and 1,133 cases were cancer-related deaths. This number puts the percentage of cancer-related deaths at 17.2%. Male patients accounted for 54.0%, and female patients are 46.0%. Breast cancer accounted for the highest mortality, followed by prostate cancer. The highest number of deaths were recorded in 2010 at 821, followed by 2011 at 799, 2015 at 780, and the least in 2017 at 513. There is also a significant general increase in odds of mortality with an increase in decades of life. CONCLUSION: This study shows that about one in five deaths, over the last ten years, from this tertiary institution, is related to a cancer diagnosis. Even though a yearly decline in the number of cancer deaths was noticed, probably due to increased awareness and governmental intervention, the percentage still remains high.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...